Septerna, Inc.
- Last sale
- Nov 12, 2026 · -13.74%
- Market cap
- $1.99B
- 47.55M shares
- Filings
- 179
Q3 2026+4,174.5% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−49.3% FY25 yoy
- $1.99B
- —
- 20.7×
- 4.6×
- -3.90%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $45,951,000 | reported | |
| FY 2024 | 2024-12-31 | $1,075,000 | reported | |
| FY 2023 | 2023-12-31 | $151,000 | reported |
Pharmaceutical preparations
Septerna, Inc. is the 131st largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
LXRXLexicon Pharmaceuticals, Inc.$49.8M729.9%101.1%$812.6MGOSSGossamer Bio, Inc.$48.5M57.7%351.5%$68.0MPTGXProtagonist Therapeutics, Inc$46.0M89.4%282.8%$8.8B
SEPNSepterna, Inc. (this company)$46.0M4,174.5%106.4%$2.0B
AQSTAquestive Therapeutics, Inc.$44.5M22.6%188.1%$448.7MCPIXCumberland Pharmaceuticals Inc$44.5M17.6%6.4%$98.4MINBPIntegrated Biopharma Inc$43.9M19.3%6.5%$9.1MXLOXilio Therapeutics, Inc.$43.8M589.9%80.1%$58.3MWVEWave Life Sciences, Inc.$42.7M60.5%478.3%$622.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Septerna, Inc. · CIK 1984086 · Engraved from SEC EDGAR